Skip to main content
Caplight Logo









Neumous

Neumous

Private
South KoreaHealthcare & Life Scienceshttps://neumous.com/

Last Round

Series A

Jul 1, 2025

Total Funding Raised

$13.71M

Company Overview

Neumous is a medical device company that develops non-invasive therapeutic ultrasound technology to open the blood-brain barrier, enabling the delivery of drugs to treat brain diseases such as tumors and Alzheimer's.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Hardware Sales, Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

blood-brain barrier openingBBB openingfocused ultrasoundtherapeutic ultrasoundbrain drug deliveryneurotechnologydrug delivery platformmedical devicesMedTechdrug repositioningAlzheimer's treatmentbrain tumor treatmentclinical trialspharmaceutical partnershipsreal-time monitoring

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Neumous Comparables

Compare Neumous with similar companies based on industry and business-model similarity.

Neumous comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Delsona Therapeutics
87%
Cordance Medical
83%
Deepson Bio
81%

Neumous Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AJul 1, 2025
GrantApr 1, 2024
GrantJun 1, 2023
GrantApr 1, 2023
SeedApr 1, 2023

Neumous Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 1, 2025

    $7M round led by SL Investment.

  • Apr 1, 2024

    $1.2M grant from Ministry of Health and Welfare (South Korea)

Neumous Filings

Explore SEC and related filing metadata, where available.

Neumous filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Neumous's valuation, stock price, and market status.

Is Neumous a public or private company?

Neumous is a private company.

What is the current stock price of Neumous?

Neumous is a private company with no public stock price. No recent secondary market data is available.

How much is Neumous worth (valuation)?

Valuation information for Neumous is not publicly available.

Can I buy Neumous stock?

Neumous shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Neumous's last funding round?

Neumous's most recent funding round was Series A on July 1, 2025.

Who are the main investors in Neumous?

Key investors in Neumous include SL Investment.

Will Neumous IPO soon?

No public IPO plans have been announced for Neumous.

How can I track Neumous secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Neumous's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSouth Korea
Year Founded2022
Last FundingJul 1, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?